Daiichi Sankyo To Be Engaged In Ranbaxy’s Problems With U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo plans to come to the aid of its recently acquired Ranbaxy Laboratories as the Indian drug maker attempts to handle accusations by U.S. FDA. Daiichi Sankyo President Takashi Shoda said his company would be actively engaged in the dealings between the two parties. The FDA blackballed two Ranbaxy plants earlier this year on grounds the drug maker submitted falsified data. Shoda said Daiichi is completing plans to address the problems cited by the FDA. (Click here for more - a subscription may be required
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.